WIXLIB

Boston Scientific 2020 Annual ReportA Message to Our Stockholders1Dear Stockholders: Over the last year, the global pandemic, political strife and racial injustice havetested us — and our business — as never before. These challenges, however, have not derailed BostonScientific from our mission to transform lives through medical solutions that improve the health ofpatients around the world.Throughout 2020, our teams worked nimbly and quickly to supportcustomers, manage costs and put strategies in place to navigatethrough uncertainty. We enhanced our digital capabilities to servecustomers in new ways, launched innovative products and touchedthe lives of close to 30 million patients. We contributed morethan 18 million in aid to global COVID-19 relief efforts, throughmonetary and supply donations and by volunteering and providingengineering and manufacturing expertise and resources. We alsostrengthened our commitment to diversity, equity and inclusionand took action to confront racism and advance social justice.The unmet needs in healthcare are great, and we have much workto do, but I’m proud of our successes and know they have beenpossible because of the incredible winning spirit of our 38,000employees and the values that define and guide our company.As a result of the agility and resilience our teams have shown, ourbusiness remains strong, and we believe we are well-positionedto return to consistent growth when the pandemic subsides andmedical procedure volumes resume.2020 Business ResultsThe decline and deferral of elective procedures due to thepandemic affected our revenue and earnings. As a result, our2020 financials are an exception to what has been a nearlysix-year trend of excellent performance.Our full-year net sales in 2020 were 9.913 billion. This representsdeclines of 7.8 percent on an operational1 basis and 11.3 percenton an organic2 basis compared to 2019, both of which includea 170-basis point impact associated with the conversion of U.S.WATCHMAN customers to a consignment inventory model andtransition to the next-generation WATCHMAN FLX Left AtrialAppendage Closure (LAAC) Device. Organic2 revenue declined by6.7 percent in MedSurg , by 13.4 percent in Rhythm and Neuro,and by 13.1 percent in Cardiovascular.3 Outside of our threereporting segments, our Specialty Pharmaceuticals4 businessgenerated revenue of 219 million. Our worldwide performancereflected the effects of COVID-19, with declines in operational1revenue of 9.7 percent in the United States, 8.4 percent in EMEA,7.1 percent in APAC, and 15.2 percent in Latin America and Canadacompared to 2019. Annual sales in Emerging Markets5 countrieswere also affected, declining 9.2 percent on an operational1 basis.Our adjusted operating margin6 for the full year was 19.3 percent,with adjusted earnings per share6 of 0.96, compared to 1.58a year ago. This reflects the impact of reduced procedurevolumes due to COVID-19 as well as the discontinuation of theLOTUS Edge Aortic Valve System and impact from the shift to theconsignment model for the WATCHMAN franchise. Despite thesechallenges, we generated 2 billion in adjusted free cash flow,7with free cash flow 8 of 1.1 billion.With our innovative pipeline, strong commercial presence andongoing expansion into higher growth markets, we continue toexecute against our strategic plan objectives and drive towardsex-COVID-199 financial goals for 6-8% organic2 sales growth,expanded adjusted operating margins6 and double-digit adjustedearnings per share6 growth. We believe this momentum, combinedwith our ability to generate and deploy strong free cash flow,positions Boston Scientific well to create future shareholder value.Positioned for GrowthBoston Scientific products are used to help diagnose or treatcomplex diseases and conditions across multiple fields: cardiovascular, respiratory, digestive, neurological, urological and pelvichealth. By deepening our portfolio in these areas, our categoryleadership strategy creates value for patients, physicians andpayors. We believe our strong balance sheet and businesseswill enable us to continue to pursue growth and expand ourpresence in new markets and regions and make our technologiesaccessible to more people in need. As of December 31, 2020,we had 1.7 billion in cash on hand, which will enable us tocontinue to make strategic, growth-enhancing investments.1 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 6 and 7. 2 Organic revenue growth rates are non-GAAP measures that exclude the impact offoreign currency fluctuations and net sales from recent acquisitions and divestitures with less than a full year of comparable net sales. See non-GAAP reconciliations on pages 6 and 7. 3 We have three reportable segments comprised of Medical Surgical(MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices). We have included the results of BTG’s Interventional Medicinebusiness in our Peripheral Interventions operating segment since the date of acquisition. 4 As part of our acquisition of BTG, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals), a stand-alone operating segment presentedalongside our Medical Device reportable segments. On March 1, 2021, we completed the sale of the Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, affiliates of SERB, for a purchase price of 800 million. 5 We defineEmerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare sectors, and our global capabilities in our Medical Devices business. Currently, we include 20 countries in ourdefinition of Emerging Markets. 6 Adjusted operating margin and adjusted earnings per share and related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense; goodwilland intangible asset impairment charges; acquisition/divestiture-related net charges and credits; restructuring and restructuring-related net charges and credits; certain litigation-related net charges and credits, investment gains and losses, EU MDRimplementation charges, debt extinguishment charges, discrete tax items and deferred tax expenses (benefits). See non-GAAP reconciliations on pages 6 and 7. 7 Adjusted free cash flow is a non-GAAP measure that excludes net purchases of property,plant and equipment, as well as the cash component of certain charges (credits) that are excluded from adjusted net income, in addition to any cash tax benefits of such charges. Further, we exclude from this measure tax settlement payments that relate toprior periods. The GAAP measure that is most directly comparable to adjusted free cash flow is cash provided by operating activities. See non-GAAP reconciliations on pages 6 and 7. 8 Free cash flow is a non-GAAP measure that excludes net purchases ofproperty, plant and equipment. The GAAP measure that is most directly comparable to adjusted free cash flow is cash provided by operating activities. See non-GAAP reconciliations on pages 6 and 7. 9 Growth goals ex-COVID-19 represent comparisonsbetween time periods in which results are not materially impacted by the COVID-19 pandemic.

2Boston Scientific 2020 Annual ReportA Message to Our StockholdersOur acquisition of Lumenis LTD, which is expected to close in thesecond half of 2021, positions Boston Scientific to accelerate thedelivery of our stone management offerings to more urologistsand expand our global footprint throughout Europe and Asia.We are pursuing opportunities to advance access to healthcarein Emerging Markets.5 In China, we target a return to double-digitgrowth in 2021 and are focused on increasing access to our productsand technologies with the opening of our Institute for AdvancingScience (IAS) in Chengdu. The new facility allows us to combine ourglobal resources with the expertise of local partners to acceleratethe development of and access to healthcare in western China.We also continue to expand our global digital capabilities. Asilver lining of adapting to the COVID-19 pandemic has been thecompany’s accelerated execution of digital and virtual solutionsin healthcare and greater use of remote monitoring technologyin many regions. We’ve increased our investments in customerand patient engagement, medical education, clinical trial remotecase support, sales force enablement and mobile ordering andsolutions. We consider these platforms a catalyst for growth andstructural costs savings over time.Addressing Critical Needs ThroughMeaningful InnovationOur research and development teams surmount the limitationsof current technology and addres

between time periods in which results are not materially impacted by the COVID-19 pandemic. Boston Scientific 2020 Annual Report A Message to Our Stockholders 1 Dear Stockholders: Over the last year, the global pandemic, political strife and racial injustice have tested us — and our business — as never before. These challenges, however, have not derailed Boston Scientific from our mission .